MARLBOROUGH, Mass., Oct. 21, 2025 — Hologic Inc., a leading U.S. medical diagnostics firm specializing in women’s health, announced on Tuesday that it will be acquired by investment firms Blackstone and TPG in a transaction valued at up to $18.3 billion Reuters | MSN MedTech Intelligence.
Deal Structure
Under the terms of the agreement, shareholders will receive $76 per share in cash, plus a contingent value right (CVR) of up to $3 per share tied to revenue milestones in Hologic’s breast health business in fiscal years 2026 and 2027. This brings the potential total consideration to $79 per share, representing a 46% premium to Hologic’s stock price before reports of the deal surfaced investors.hologic.com.
The transaction, which includes minority investments from sovereign wealth funds such as ADIA and GIC, is expected to close in 2026 pending regulatory and shareholder approvals.
Strategic Context
Hologic, best known for its breast and cervical cancer screening technologies, has faced waning demand since the COVID‑19 pandemic and rising competition in diagnostics. The company said the deal would provide resources to accelerate growth and strengthen its leadership in women’s health.
Blackstone and TPG, both experienced in healthcare investments, described the acquisition as a long‑term bet on the expanding global demand for women’s health diagnostics.
Market Reaction
Hologic’s shares rose nearly 4% in early trading following the announcement. The stock has gained more than 13% over the past month, buoyed by speculation of renewed buyout talks Reuters | MSN.
Industry Significance
The acquisition ranks among the largest healthcare take‑private deals of 2025, underscoring private equity’s growing role in reshaping the sector. Analysts note that the deal reflects investor confidence in the resilience of women’s health diagnostics, even as broader medtech markets face pricing pressures and regulatory scrutiny.
Summary: Hologic will be taken private in an $18.3 billion acquisition by Blackstone and TPG, with shareholders set to receive up to $79 per share. The deal, one of the year’s biggest in healthcare, highlights both the challenges facing diagnostics firms post‑pandemic and the strategic value of women’s health technologies.
Sources: Reuters Reuters | MSN; MedTech Intelligence MedTech Intelligence; Hologic Investor Relations investors.hologic.com.
